LIPO News and Press, Lipella Pharmaceuticals Inc. From 02/11/25

2025-02-11 12:10:00 ET A biotech company is turning heads so far during Tuesday’s session after it shared topline analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus (OLP), according...

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Rec...

2025-02-06 11:50:29 ET ON YOUR RADAR DENVER, Colo., Feb 06, 2025 ( 247marketnews.com )- 24/7 Market News, a trusted source for real-time financial news and market analysis, highlights today’s most significant stock movements and breaking developments shaping the financial lan...

PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Dru...

New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC , a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole ...